Functional studies using human cancer cell lines have shown that, in contrast to V600E mutants, ∆NVTAP mutants are resistant to BRAF monomer inhibitors such as vemurafenib and dabrafenib that target the ‘αC-out/DFG-in’ structural conformation of the active protein kinase. This evidence concerns the gene BRAF and cancer.